SSY Group Receives Approval for Levamlodipine Besilate Tablets to Treat Hypertension in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2025
0mins
Source: NASDAQ.COM
Approval Announcement: SSY Group Limited has received approvals from China's National Medical Products Administration for Levamlodipine Besilate Tablets (5mg and 2.5mg), classified as type 4 chemical drugs.
Therapeutic Use: The tablets are indicated for treating hypertension, providing options for both standalone and combination therapy to effectively manage elevated blood pressure and reduce cardiovascular risk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
